Clinical outcomes | Yang et al. [26] | Bailey et al. [25] | Kaminski et al. [34] | Everhart et al. [33] | Dai et al. [19] | Kemmochi et al. [32] | Kaminski et al. [31] | Pujol et al. [30] | Griffin et al. [20] | |
---|---|---|---|---|---|---|---|---|---|---|
IKDC score | PRP | 75.1 ± 13.6 | 87.6 ± 13.3 |  |  |  | 87.4 ± 10.4 | 97.56 ± 0.63 | 90.7 | 69 ± 26 |
Control | 72.6 ± 15.8 | 88.1 ± 12.6 |  |  |  | 91.5 ± 1.2 | 84.77 ± 0.92 | 87.9 | 76 ± 17 | |
P value | 0.593 | 0.952 | Â | Â | Â | 0.13 | 0.001 | Â | 0.288 | |
Lysholm knee scale | PRP | 80.6 ± 14.9 |  |  |  | 79.8 ± 9.6 | 95.8 ± 7.1 |  |  | 66 ± 31.9 |
Control | 77.7 ± 17.2 |  |  |  | 74.6 ± 11.6 | 97.2 ± 1.8 |  |  | 89 ± 9.7 | |
P value | 0.670 | Â | Â | Â | 0.306 | 0.69 | Â | Â | 0.065 | |
VAS score | PRP |  |  | 1.97 ± 0.05 |  | 1.2 ± 1.0 |  | 0.84 ± 0.10 |  |  |
Control |  |  | 2.05 ± 0.08 |  | 1.6 ± 1.1 |  | 0.89 ± 0.08 |  |  | |
P value | Â | Â | 0.39 | Â | 0.321 | Â | 0.15 | Â | Â | |
SANE score | PRP |  | 91.6 ± 11.2 |  |  |  |  |  |  |  |
Control |  | 92.4 ± 10.6 |  |  |  |  |  |  |  | |
P value | Â | 0.599 | Â | Â | Â | Â | Â | Â | Â | |
WOMAC score | PRP |  |  | 9.72 ± 0.32 |  |  |  | 0.95 ± 0.13 |  |  |
Control |  |  | 7.50 ± 0.59 |  |  |  | 3.95 ± 0.33 |  |  | |
P value | Â | Â | 0.21 | Â | Â | Â | 0.002 | Â | Â | |
Tegner activity level score | PRP |  |  |  |  |  | 5.9 ± 2.3 |  |  |  |
Control |  |  |  |  |  | 7.8 ± 1.6 |  |  |  | |
P value | Â | Â | Â | Â | Â | 0.11 | Â | Â | Â | |
Failure rate | PRP | 6.7% | Â | 48.0% | 14.6% | 7.1% | Â | 15% | 5.8% | 26.7% |
Control | 12.9% | Â | 70.0% | 17.0% | 13.3% | Â | 53% | 11.8% | 25.0% | |
P value | 0.874 | Â | 0.04 | 0.60 | 0.58 | Â | 0.048 | 0.54 | 0.89 | |
KOOS | ||||||||||
(i) Pain | PRP |  |  | 87.24 ± 0.36 |  |  |  | 96.06 ± 0.23 | 93.3 |  |
Control |  |  | 89.00 ± 0.63 |  |  |  | 92.85 ± 0.43 | 78.4 |  | |
P value | Â | Â | 0.22 | Â | Â | Â | 0.035 | 0.046 | Â | |
(ii) Symptoms | PRP |  |  | 92.03 ± 0.27 |  |  |  | 96.23 ± 0.31 | 90.9 |  |
Control |  |  | 90.42 ± 0.56 |  |  |  | 92.33 ± 0.48 | 86.1 |  | |
P value | Â | Â | 0.27 | Â | Â | Â | 0.029 | Â | Â | |
(iii) ADL | PRP |  |  | 89.36 ± 0.36 |  |  |  | 98.18 ± 0.13 | 97.2 |  |
Control |  |  | 92.38 ± 0.61 |  |  |  | 95.14 ± 0.38 | 93.8 |  | |
P value | Â | Â | 0.25 | Â | Â | Â | 0.0004 | Â | Â | |
(iv) Sport/recreation | PRP |  |  | 69.52 ± 0.77 |  |  |  | 89.44 ± 0.86 | 88.8 |  |
Control |  |  | 78.98 ± 1.10 |  |  |  | 77.56 ± 1.26 | 74.4 |  | |
P value | Â | Â | 0.11 | Â | Â | Â | 0.009 | 0.03 | Â | |
(v) QoL | PRP |  |  | 67.06 ± 0.55 |  |  |  | 80.90 ± 1.09 | 78.3 |  |
Control |  |  | 68.18 ± 1.08 |  |  |  | 66.18 ± 1.17 | 74.6 |  | |
P value | Â | Â | 0.42 | Â | Â | Â | 0.008 | Â | Â |